Angelman Syndrome Race Heats Up: $175M Backs Roche's Shelved Drug

References

1. 1.Mast, J. (2026, July 27). RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease. STAT News. https://www.statnews.com/2026/07/27/ra-captial-oak-hill-bio-spac-ultragenyx-ionis-angelman-syndrome/
2. 2.Thibert, R. L., Larson, A. M., Hsieh, D. T., Raby, A. R., & Thiele, E. A. (2013). Neurologic manifestations of Angelman syndrome. Pediatric Neurology, 48(4), 271–279. https://doi.org/10.1016/j.pediatrneurol.2012.09.015
3. 3.Bindels-de Heus, K. G. C. B., Mous, S. E., Ten Hooven-Radstaake, M., van Iperen-Kolk, B. M., Navis, C., Rietman, A. B., Brooks, A. S., Elgersma, Y., Moll, H. A., & de Wit, M. Y. (2020). An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. American Journal of Medical Genetics Part A, 182(5), 1268–1279. https://doi.org/10.1002/ajmg.a.61852
4. 4.Meng, L., Ward, A. J., Chun, S., Bennett, C. F., Bhatt, D. L., & Bhatt, D. L. (2015). Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature, 518(7539), 409–412. https://doi.org/10.1038/nature15327
5. 5.Milazzo, C., Mientjes, E. J., Wallaard, I., Rasmussen, S. V., Johannessen, K. H., Erichsen, K. D., Van der Sman, A. S. E., Kakunuri, S., Elgersma, Y., & Bhatt, D. L. (2021). Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight, 6(15), e145991. https://doi.org/10.1172/jci.insight.145991
6. 6.Australian Genomics. (2023). Genomics in newborn screening: Australian policy landscape and implementation considerations. Australian Genomics Health Alliance. https://www.australiangenomics.org.au
7. 7.Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 316(8), 858–871. https://doi.org/10.1001/jama.2016.11237
8. 8.Frampton, J. E. (2023). Antisense oligonucleotides: A review of their use in rare neurological diseases. Drugs, 83(14), 1291–1328. https://doi.org/10.1007/s40265-023-01870-3
9. 9.Pharmaceutical Benefits Advisory Committee (PBAC). (2024). PBAC guidelines: Submissions to list medicines on the Pharmaceutical Benefits Scheme. Australian Government Department of Health and Aged Care. https://www.pbs.gov.au/industry/listing/elements/pbac-guidelines/pbac-guidelines.pdf